Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters

Breast Cancer - HER2 Positive Clinical Trials

A listing of Breast Cancer - HER2 Positive medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (34) clinical trials

You are being asked to participate in this study because you are a postmenopausal woman with estrogen receptor positive and HER2 negative breast cancer that no longer responds to aromatase inhibitors (anti-estrogen therapy) and has spread in the breast, or to other parts of your body. For patients who receive ...

Phase

You are being asked to take part in this study because you are a woman/man with hormone responsive breast cancer that has already been removed by surgery and you have completed any required chemotherapy or radiation. The purpose of this study is to see whether treatment with everolimus plus hormone ...

Phase

The target population for this study is women who are candidates to receive single agent fulvestrant endocrine therapy for metastatic, ER/PR+ and HER2 negative breast cancer. Such patients shall not have received prior treatment with chemotherapy in the locally advanced or metastatic disease setting and must have failed prior systemic ...

Phase

A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast Cancer

The American Society of Clinical Oncology (ASCO) Clinical Practice Guidelines recommend the use of pertuzumab, trastuzumab and taxane as first-line treatment for patients with MBC. As a second-line treatment, trastuzumab emtansine (T-DM1) is also recommended. After a pertuzumab-containing regimen and T-DM1, other HER2-targeted therapeutic regimens, including lapatinib-containing regimens and trastuzumab ...

Phase

Preoperative Combination of Letrozole Everolimus and TRC105 in Postmenopausal Hormone-Receptor Positive and Her2 Negative Breast Cancer

In postmenopausal women with hormone receptor-positive and Her2 negative non-metastatic breast cancer, downstaging or the achievement of a complete pathologic remission before definitive surgery has been associated with the lowest risk of recurrence of breast cancer. In order to achieve a better response in these patients in the preoperative setting, ...

Phase

Phase III Study of Palbociclib (PD-0332991) in Combination With Endocrine Therapy (Exemestane or Fulvestrant) Versus Chemotherapy (Capecitabine) in Hormonal Receptor (HR) Positive/HER2 Negative Metastatic Breast Cancer (MBC) Patients With Resistance to Non-steroidal Aromatase Inhibitors

Approximately 250 patients will be randomized 1:1 between the experimental arm (Arm A: approximately 125 patients treated with palbociclib plus exemestane) and the control arm (Arm B: approximately 125 patients treated with capecitabine) before the approval of this protocol version (Cohort 1). Approximately 300 patients will be randomized 1:1 between ...

Phase

A Phase III Trial Comparing Two Dose-dense Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)

Several recent strategies have improved efficacy of systemic treatment for patients with high-risk early stage breast cancer: the addition of a dual HER2-blockade for HER2-positive; the implementation of carboplatin for TNBC and the use of dose-dense or dose-dense, dose escalated chemotherapy in all high-risk subtypes of breast cancer. Two regimen ...

Phase